TELA Bio
Life science company offering surgical reconstruction.
Launch date
Employees
Market cap
CAD89.3m
Enterprise valuation
CAD110m (Public information from Sep 2024)
Share price
$2.68 TELA
Company register number 11425433
Malvern Iowa (HQ)
Financials
Estimates*
| USD | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenues | 15.4m | 18.2m | 29.5m | 41.4m | 58.5m | 74.4m | 92.8m |
| % growth | 87 % | 18 % | 62 % | 41 % | 41 % | 27 % | 25 % |
| EBITDA | (18.8m) | (25.2m) | (29.7m) | (39.0m) | (40.6m) | - | - |
| % EBITDA margin | (122 %) | (139 %) | (101 %) | (94 %) | (70 %) | - | - |
| Profit | (22.4m) | (28.8m) | (33.3m) | (44.3m) | (46.7m) | - | - |
| % profit margin | (145 %) | (158 %) | (113 %) | (107 %) | (80 %) | - | - |
| R&D budget | 4.2m | 4.3m | 6.7m | 8.9m | 9.6m | - | - |
| R&D % of revenue | 27 % | 23 % | 23 % | 22 % | 16 % | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | $6.0m | Growth Equity VC | |
| N/A | $45.4m | Early VC | |
| N/A | $500k | Early VC | |
| N/A | $7.4m | Early VC | |
$25.0m | Growth Equity VC | ||
$1.0m | Early VC | ||
| N/A | Series B | |
| N/A | $500k | Early VC | |
| N/A | $2.1m | Early VC | |
| N/A | N/A | IPO | |
| N/A | $48.0m | Post IPO Equity | |
* | N/A | $32.0m | Post IPO Equity |
* | N/A | $45.1m | Post IPO Equity |
| Total Funding | CAD120m | ||
Related Content
Recent News about TELA Bio
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.